RT Journal Article
SR Electronic
A1 Kuznar, Wayne
T1 Investigational Selective JAK1 Inhibitor Improves Measures of Disease Activity in RA
JF MD Conference Express
YR 2013
FD SAGE Publications
VO 13
IS 8
SP 18
OP 18
DO 10.1177/155989771308008
UL http://mdc.sagepub.com/content/13/8/18.abstract
AB An investigational selective inhibitor of Janus kinase 1 (JAK1) was found to improve clinical endpoints with a favorable safety profile in a Phase 2a dose-ranging study of patients with rheumatoid arthritis (RA). This article discusses the results of a 4-week double-blind, placebo-controlled study of GLPG0634, an orally-available, selective inhibitor of JAK1, in patients with active RA [Vanhoutte FP et al. EULAR 2013 (poster 0229)].